DiaMedica Therapeutics (DMAC) Corporate presentation summary

Market opportunity and unmet need

• Preeclampsia and fetal growth restriction represent a $5B+ U.S. market with no approved disease-modifying therapies; acute ischemic stroke is a $10B+ U.S. market with significant unmet need, as ~80% of patients lack effective treatment options.

Lead program and mechanism of action

• DM199 is a recombinant human KLK1 protein with a novel mechanism, producing all three major endothelial-derived vasodilators (NO, prostacyclin, EDHFs), improving blood flow and reducing blood pressure.

• DM199 does not cross the placental barrier, supporting its safety profile in pregnancy.

Clinical development and results

• Ongoing and planned phase 2/3 trials for preeclampsia, fetal growth restriction, and acute ischemic stroke, with interim phase 2 data showing significant blood pressure reduction and improved uterine artery perfusion.

• DM199 demonstrated favorable safety and tolerability, with no serious treatment-emergent adverse events and no placental transfer detected.

• In acute ischemic stroke, DM199 improved clinical outcomes in phase 2, offering a 24-hour treatment window and showing efficacy comparable to or better than tPA in relevant populations.